Landscapes / Companies
Beijing Biotech not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
31 in Phase 2
2 in Phase 1
Drugs
33
in active trials
Trials
32 active
32 since 2021
Drugs33
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Glioblastoma and 17 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Metastatic Solid Tumors and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed Neuroblastoma, Refractory Neuroblastoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Colorectal Cancer Metastatic, Adenocarcinoma of Colon and 3 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021